

Contract Number	Amount Obligated	Total Estimated Contract Value	Center	Awardee Name	Awardee Address	Column1	Column2	BAA Number	Award Title
75F40125C00073	\$661,012.30	\$661,012.30 CDER	SimVantage GmbH		SIMVANTAGE GMBH Inffeldgasse 13 Graz 8010	Charge I	Topic B	FY25C1BP3	Combining Machine Learning and Mechanistic Models to Create a Digital Framework for Rapidly Designing Continuous Bioprocess Operations
75F40125C00085	\$324,978.00	\$324,978.00 CDER	Hartford Hospital		80 Seymour St PO Box 5037 Hartford, CT 06102	Charge III	Topic B	FY25C3BP2	Pharmacodynamics of Daptomycin against Enterococcus faecium and Enterococcus faecalis in the Murine Thigh Infection Model
75F40125C00095	\$3,090,714.59	\$3,090,714.59 OCS	Vahan Simonyan		3909 Fox Valley Rd Rockville,MD 20853	Charge III	Topic A	FY25C3AP3	HIVE 2.0 (H2O) – a next generation medical countermeasures scientific platform for regulatory evaluation and preparedness
75F40125C00089	\$999,347.00	\$999,347.00 CDER	Rutgers University		3 RUTGERS PLAZA NEW BRUNSWICK NJ 089018559	Charge I	Topic B	FY25C1BP27	Development and implementation of AI/ML toolbox for digitalization of advanced modular continuous API manufacturing process
75F40125C00069	\$1,085,530.00	\$1,085,530.00 CDER	Genentech Inc.		GENENTECH, INC. 1 DNA WAY SOUTH SAN FRANCISCO CA 94080	Charge I	Topic F	FY25C1FP4	Novel hybrid randomized clinical trial designs for longitudinal outcomes with applications to rare disease settings
75F40125C00075	\$1,064,238.00	\$1,064,238.00 OCE	The University of Texas MD Anderson Cancer Center		THE UNIVERSITY OF TEXAS M D ANDERSON CANCER 1515 HOLCOMBE BLVD Box 1676 HOUSTON TX 77030	Charge I	Topic F	FY25C1FP6	Statistical designs and considerations for dose optimization with drug combination and multiple indications
75F40125C00072	\$799,998.00	\$799,998.00 CDER	The University of Mississippi		THE UNIVERSITY OF MISSISSIPPI SPONSORED PROGRAMS ADMINISTRATION UNIVERSITY OF MISSISSIPPI The National Center for Natural Products Research (NCNPR), P.O. Box 1848 100 Barr Hall UNIVERSITY MS 386779704	Charge I	Topic C	FY25C1CP32	Quality and Safety of Botanical Products: Addressing Herb-Drug Interactions in Healthy Individuals
75F40125C00105	\$2,277,208.00	\$2,277,208.00 CDRH	Florida State University, Center of Population Sciences for Health Equity		874 Traditions Way Tallahassee, FL 32306	Charge III	Topic C	FY25C3CP4	Modernizing and Decentralizing Clinical Trials with AI, Digital Health, and Community-Driven Innovation to Deliver Better Health for All Americans
75F40125C00034	\$867,755.00	\$1,981,317.00 CTP	The Ohio State University College of Public Health		OHIO STATE UNIVERSITY, THE 1960 KENNY RD COLUMBUS OH 43210	Charge I	Topic C	FY25C1CP40	The Determination of Repeatability (r) and Reproducibility (R) for the measurement of total particulate matter and nicotine in combustible and electronic nicotine delivery systems (ENDS) using a universal smoking machine adaptor (USMA).
75F40125C00054	\$1,138,631.00	\$1,138,631.00 OCE	Johns Hopkins University School of Medicine		W-400 WYMAN PARK 3400 N CHARLES ST JOHNS HOPKINS UNIVERSITY BALTIMORE MD 21218265	Charge II	Topic D	FY25C2DP7	Application of Computable Phenotyping to Real-World Data to Support the Active Safety Surveillance of CAR T-cell Therapies
75F40125C00071	\$492,000.00	\$1,265,103.00 OCET	University of Maryland, Baltimore		UNIVERSITY OF MARYLAND, BALTIMORE 220 ARCH STREET, OFFICE LEVEL 2 BALTIMORE MD 212011531	Charge III	Topic A	FY25C3AP15	Noninvasive Fingerprinting of Aluminum-adjuvanted Vaccines
75F40125C00053	\$749,661.00	\$749,661.00 CDRH	Duke University		Duke University 2200 WEST MAIN STREET SUITE 300 DURHAM NC 27705	Charge I	Topic I	FY25C1IP7	Quantifying Patient Preference Information in Small-Scale Studies for Regulatory Decision Making
75F40125C00049	\$288,274.00	\$288,274.00 CDER	University of Maryland Baltimore		THE STATE OF MARYLAND 1378167 UNIVERSITY OF MARYLAND BALTIMORE 601 W LOMBARD ST BALTIMORE MD 21201	Charge III	Topic B	FY25C3BP5	Developing studies needed to define clinical and/or surrogate endpoints that can be used for the regulatory approval of decolonizing agents, microbiome therapies, or similar products
75F40125C00063	\$515,769.89	\$515,769.89	Universitat St Gallen		DUFOURSTRASSE 40A ST. GALLEN SG 9000	Charge II	Topic D	FY25C2DP1	RiskExcellence – Complementing Risk-Based Surveillance

75F40125C00009	\$496,171.00	\$496,171.00 CDRH	DIGITAL MEDICINE SOCIETY INC 90 CANAL ST FL 4, BOSTON MA 02114	Charge I	Topic I	FY24C1IP4	Vision 2030: Strategic roadmap for implementing patient voice into the total product lifecycle for medical devices via patient-generated health data
	\$14,851,287.78	\$16,737,952.78					